Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Efficacy of Using Interleukin-2 in Antiretroviral Naïve HIV Patients (ANRS119)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00120185
Recruitment Status : Completed
First Posted : July 15, 2005
Last Update Posted : December 22, 2011
Chiron Corporation
Information provided by (Responsible Party):
French National Agency for Research on AIDS and Viral Hepatitis

Brief Summary:
Interleukin-2 (IL-2) increases the number of CD4 cells in HIV-1 infected patients under highly active antiretroviral therapy (HAART) with a CD4 cell count over 200/mm3, but its activity in patients without antiretroviral therapy is unknown. This study will test the efficacy and safety of IL-2 in naïve patients with a CD4 count between 300 and 500/m3.

Condition or disease Intervention/treatment Phase
HIV Infections Drug: Interleukin-2 Phase 2

Detailed Description:
IL-2 is produced naturally in the body and helps CD4 cells multiply. In earlier studies in HIV-infection, most of the patients with a controlled viral load under antiretroviral therapy and a high level of CD4 cell count (over 200/mm3) who received IL-2, experienced an increase of their CD4 cell count superior to what is observed with antiretroviral therapy alone. The efficacy of IL-2 when the viral load is high and the patient is not receiving antiretroviral therapy is not known. The purpose of this multicentric national study is to compare the effects of IL-2 versus no treatment in HIV naïve patients. One hundred thirty HIV-1-infected patients, with a CD4 count between 300 and 500/mm3, will be randomly assigned to one of two treatment groups : IL-2 or no treatment. The group with IL-2 will receive a dose of 4.5 million international units by subcutaneous injection twice a day for 5 days (up to a total of 5 cycles, ending at Week 96), the first three cycles 8 weeks apart. Evaluation will be done at week 96. The primary endpoint is the proportion of patients reaching an absolute CD4 count below 300/mm3 at Week 96. Secondary endpoints include the occurrence of HIV-related events, drug safety and the evolution of CD4 cells and of HIV RNA and HIV DNA loads over time.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 130 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Study of the Immunological Efficacy of Using Subcutaneous Interleukin-2 (IL-2) in Antiretroviral Naïve HIV-1-Infected Subjects With a CD4 Cell Count Above 300/mm3. ANRS 119 Trial INTERSTART
Study Start Date : December 2003
Actual Primary Completion Date : November 2006
Actual Study Completion Date : November 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Primary Outcome Measures :
  1. Proportion of patients reaching an absolute CD4 count below 300/mm3 at W96

Secondary Outcome Measures :
  1. Group B or C events (1993 CDC classification of HIV infection)
  2. Initiation of antiretroviral therapy
  3. Evolution of the CD4 count during the study
  4. Time to the first visit with a CD4 count below 300/mm3
  5. Tolerance of IL-2
  6. Evolution of the plasma HIV RNA load
  7. Evolution of the HIV DNA level in PBMCs
  8. Quality of life at W96
  9. Assessment of lipodystrophy at W96
  10. Immunological substudies (CD4 homeostasis, anti HIV cellular immune responses) at W96

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adult patients with proven HIV-1-infection
  • No prior exposition to antiretrovirals
  • CD4 cell count between 300 and 500/mm3
  • Signed written inform consent

Exclusion Criteria:

  • Pregnancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00120185

Layout table for location information
Service des Maladies Infectieuses
Paris, France, 75010
Sponsors and Collaborators
French National Agency for Research on AIDS and Viral Hepatitis
Chiron Corporation
Layout table for investigator information
Principal Investigator: Jean-Michel Molina, MD Hopital Saint Louis Paris service des Maladies infectieuses et Tropicales
Study Chair: Jean-Pierre Aboulker, MD Inserm SC10
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: French National Agency for Research on AIDS and Viral Hepatitis Identifier: NCT00120185    
Other Study ID Numbers: 2004-003897-27
ANRS119 Interstart
First Posted: July 15, 2005    Key Record Dates
Last Update Posted: December 22, 2011
Last Verified: December 2011
Keywords provided by French National Agency for Research on AIDS and Viral Hepatitis:
HIV Infections
Additional relevant MeSH terms:
Layout table for MeSH terms
HIV Infections
Blood-Borne Infections
Communicable Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Antineoplastic Agents
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs